Beckley Psytech is developing a novel synthetic intranasal formulation of 5-MeO-DMT benzoate, designed to provide rapid and lasting treatment effects for mental health conditions such as Treatment Resistant Depression and Alcohol Use Disorder. The company addresses the significant unmet need for effective and accessible mental health treatments by leveraging next-generation psychedelic compounds that can be administered in a short clinic visit.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+3Founders
Product
Problem
Approximately one billion people worldwide suffer from mental disorders, yet many lack access to effective care. Existing mental health treatments can be slow to take effect, poorly tolerated, and require frequent clinic visits, creating a significant unmet need for rapid, accessible, and well-tolerated therapies. The global economic cost of mental health disorders is projected to reach $6 trillion by 2030.
Solution
Beckley Psytech is developing next-generation, short-duration psychedelic medicines to rapidly improve outcomes for individuals with mental health conditions. Their lead candidate, BPL-003, is a novel synthetic intranasal formulation of 5-MeO-DMT benzoate designed to overcome the limitations of first-generation psychedelics and existing treatments. BPL-003 is designed to be administered in a short clinic visit, is well-tolerated, and can deliver rapid, robust, and lasting treatment effects. The company collaborates with stakeholders across the mental health landscape to accelerate research and support clinical trial participants.
Target Audience
The primary target audience includes individuals suffering from Treatment Resistant Depression and Alcohol Use Disorder, as well as healthcare providers and clinical researchers in the mental health field.
Features
- Novel synthetic intranasal formulation of 5-MeO-DMT benzoate (BPL-003)
- Designed for rapid absorption and onset of therapeutic effects
- Short in-clinic administration time (less than 2 hours)
- Currently in Phase II clinical trials for Treatment Resistant Depression and Alcohol Use Disorder
- Designed to be well-tolerated, improving patient compliance